Alexandros Makriyannis

The paper profiles the efficacy of 22 cannabinoid ligands at CB1 and CB2 receptors using BRET assays, finding consistent trends in agonist efficacy and antagonist effects.

This study shows acetaminophen reduces pain by altering lipid signaling via cannabinoid receptors and enzymes in mice.

This study uses library docking to identify subtype-selective CB2 receptor ligands, finding improved hit rates and affinities with larger libraries and structure-based optimization.

This study identifies gut-derived metabolite alterations in ASD, showing distinct metabolic networks and a moderate ability to distinguish ASD from controls using a small panel of metabolites.

This study examines the behavioral effects of the neutral CB1R antagonist AM6527 in mice, finding dose-dependent reductions in reward consumption and motivated behavior, with partial dopaminergic rescue.

This study shows that CB1 agonists like CP55,940 and THC cause respiratory depression in awake mice, contradicting previous beliefs about their minimal respiratory impact.

This study identifies primary sensory neurons as the cell type mediating anti-allodynic effects of CB2 agonists and reveals a sexually dimorphic sparing of morphine tolerance in male mice.

This study shows that CB2 receptors in peripheral sensory neurons are essential for the antinociceptive effects of CB2 agonists and their ability to reverse morphine tolerance in a neuropathic pain model.